The qc results did not indicate a reagent issue.The sensitivity of the elecsys anti-sars-cov-2 assay early after infection is unknown.Negative results do not preclude acute sars-cov-2 infection.If acute infection is suspected, direct testing for sars-cov-2 is necessary.As the sample was not available, the investigation did not identify a product problem.The cause of the event could not be determined.The maglumi cmia assay does not appear to have eua (emergency use authorization) approval.(b)(6).
|
The initial reporter received a questionable anti-sars-cov-2 elecsys result for one patient from cobas e 801 module serial number (b)(4).On (b)(6) 2020, the rt-pcr result was 27.68.On (b)(6) 2020, the covidg result was 0.02 (non-reactive) and the covidm (reactive) result was 6.22 by maglumi - cmia.The anti-sars-cov-2 elecsys result was 0.0822 (non-reactive).It is unknown which result was correct.The questionable result was not reported outside of the laboratory.
|